Protein N-Glycosylation in Cardiovascular Diseases and Related Risk Factors

Current Cardiovascular Risk Reports

Volumn 12, Issue 6, 2018, Pages

  Gudelj, Ivan ^a   Lauc, Gordan ^a,b  

^a GENOS GLYCOSCIENCE RESEARCH LABORATORY   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Atherosclerosis; Biomarker; Cardiovascular disease; N Glycosylation; Risk factors

Indexed keywords

C REACTIVE PROTEIN; GLYCAN; GLYCOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; N ACETYLGLUCOSAMINE; OLIGOSACCHARIDE; PROTEOME; SIALIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ARTERY INTIMA; ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DISEASE EXACERBATION; DYSLIPIDEMIA; ETHNICITY; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; REVIEW; RISK FACTOR; SIALYLATION; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 85046797467     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-018-0579-4     Document Type: Review

References (164)

1. Wang H, Naghavi M, Allen C, Barber R, Bhutta ZA, Carter C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–544.
2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37:2315–81.
3. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics’2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.
4. Gajjala PR, Fliser D, Speer T, Jankowski V, Jankowski J. Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. Nephrol Dial Transplant. 2015;30:1814–24.
5. Pu Q, Yu C. Glycosyltransferases, glycosylation and atherosclerosis. Glycoconj J. 2014;31:605–11.
6. Ngoh GA, Facundo HT, Zafir A, Jones SP. O-GlcNAc signaling in the cardiovascular system. Circ Res. 2010;107:171–85.
7. Wright JN, Collins HE, Wende AR, Chatham JC. O-GlcNAcylation and cardiovascular disease. Biochem Soc Trans. 2017;45:545–53.
8. Freeze HH. Genetic defects in the human glycome. Nat Rev Genet. 2006;7:537–51.
9. Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: the human N-glycome. Biochim Biophys Acta. 2016;1860:1574–82.
10. Kosicek M, Gudelj I, Horvatic A, Jovic T, Vuckovic F, Lauc G, et al. N-glycome of the lysosomal glycocalyx is altered in Niemann-Pick type C disease model cells. Mol Cell Proteomics. American Society for Biochemistry and Molecular Biology; 2018;mcp.RA117.000129.
11. Keser T, Gornik I, Vučković F, Selak N, Pavić T, Lukić E, et al. Increased plasma N-glycome complexity is associated with higher risk of type 2. Diabetes. 2017;
12. Freidin MB, Keser T, Gudelj I, Štambuk J, Vučenović D, Allegri M, et al. The association between low back pain and composition of IgG glycome. Nat Publ Gr. 2016:1–11.
13. Vučković F, Krištić J, Gudelj I, Teruel Artacho M, Keser T, Pezer M, et al. Systemic lupus erythematosus associates with the decreased immunosuppressive potential of the IgG glycome. Arthritis Rheumatol (Hoboken, NJ) 2015;67:2978–2989.
14. • Barrios C, Zierer J, Gudelj I, Stambuk J, Ugrina I, Rodriguez E, et al. Glycosylation profile of IgG in moderate kidney dysfunction. J Am Soc Nephrol. 2015;1–9. A. Important: this paper shows the association of IgG N -glycome alterations with kidney disfunction.
15. • Gudelj I, Salo PP, Trbojević-Akmačić I, Albers M, Primorac D, Perola M, et al. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. Biochim Biophys Acta - Mol Basis Dis. 2018. Important: in this study, the authors found that N -glycosylation changes can precede future diagnosis of a disease for more than 10 years.
16. Lauc G. Precision medicine that transcends genomics: glycans as integrators of genes and environment. Biochim Biophys Acta - Gen Subj. 2016;1860:1571–3.
17. Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat Rev Mol Cell Biol. 2012;13:448–62.
18. Dube DH, Bertozzi CR. Glycans in cancer and inflammation—potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005;4:477–88.
19. Goreta SS, Dabelic S, Dumic J. Insights into complexity of congenital disorders of glycosylation. Biochem Med (Zagreb). 2012;22:156–70.
20. Gehrmann J, Sohlbach K, Linnebank M, Böhles H-J, Buderus S, Kehl HG, et al. Cardiomyopathy in congenital disorders of glycosylation. Cardiol Young. 2003;13:345–51.
21. Marques-da-Silva D, Francisco R, Webster D, dos Reis Ferreira V, Jaeken J, Pulinilkunnil T. Cardiac complications of congenital disorders of glycosylation (CDG): a systematic review of the literature. J Inherit Metab Dis. 2017;40:657–72.
22. Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE, et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5:320–6.
23. Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci U S A. 1997;94:13873–8.
24. Mogensen J, Klausen IC, Pedersen a K, Egeblad H, Bross P, Kruse TA, et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest 1999;103:R39–R43.
25. Marquardt T, Hülskamp G, Gehrmann J, Debus V, Harms E, Kehl H. Severe transient myocardial ischaemia caused by hypertrophic cardiomyopathy in a patient with congenital disorder of glycosylation type Ia. Eur J Pediatr. 2002;161:524–7.
26. Niehues R, Hasilik M, Alton G, Körner C, Schiebe-Sukumar M, Koch HG, et al. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest. 1998;101:1414–20.
27. Lühn K, Marquardt T, Harms E, Vestweber D. Discontinuation of fucose therapy in LADII causes rapid loss of selectin ligands and rise of leukocyte counts. Blood. 2001;97:330–2.
28. Marquardt T, Lühn K, Srikrishna G, Freeze HH, Harms E, Vestweber D. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood. 1999;94:3976–85.
29. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.
30. Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005;352:1685–95.
31. Pamukcu B, Lip GYH, Devitt A, Griffiths H, Shantsila E. The role of monocytes in atherosclerotic coronary artery disease. Ann Med. 2010;42:394–403.
32. Scott DW, Patel RP. Endothelial heterogeneity and adhesion molecules N-glycosylation: implications in leukocyte trafficking in inflammation. Glycobiology. 2013;23:622–33.
33. Scott DW, Chen J, Chacko BK, Traylor JG, Orr AW, Patel RP. Role of endothelial N-glycan mannose residues in monocyte recruitment during atherogenesis. Arterioscler Thromb Vasc Biol. 2012;32:e51–9.
34. Huo Y, Xia L. P-selectin glycoprotein ligand-1 plays a crucial role in the selective recruitment of leukocytes into the atherosclerotic arterial wall. Trends Cardiovasc Med. 2009;19:140–5.
35. Cooper D, Iqbal AJ, Gittens BR, Cervone C, Perretti M. The effect of galectins on leukocyte trafficking in inflammation: sweet or sour? Ann N Y Acad Sci. 2012;1253:181–92.
36. Peng Y, Li J, Geng M. The glycan profile of endothelial cells in the present of tumor-conditioned medium and potential roles of β-1,6-GlcNAc branching on HUVEC conformation. Mol Cell Biochem. 2010;340:143–52.
37. Chacko BK, Scott DW, Chandler RT, Patel RP. Endothelial surface N-glycans mediate monocyte adhesion and are targets for anti-inflammatory effects of peroxisome proliferator-activated receptor γ ligands. J Biol Chem. 2011;286:38738–47.
38. Diamond MS, Staunton DE, De Fougerolles AR, Stacker SA, Garcia-Aguilar J, Hibbs ML, et al. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol. 1990;111:3129–39.
39. García-Vallejo JJ, Van Dijk W, Van Het Hof B, Van Die I, Engelse MA, Van Hinsbergh VWM, et al. Activation of human endothelial cells by tumor necrosis factor-alpha results in profound changes in the expression of glycosylation-related genes. J Cell Physiol. 2006;206:203–10.
40. • Jaillet C, Morelle W, Slomianny MC, Paget V, Tarlet G, Buard V, et al. Radiation-induced changes in the glycome of endothelial cells with functional consequences. Sci Rep. 2017;7. Important: in this paper, authors showed that N -glyosylation changes are associated with functional properties of endothelial cells.
41. Sperandio M. Selectins and glycosyltransferases in leukocyte rolling in vivo. FEBS J. 2006;273:4377–89.
42. Lowe JB. Glycosylation in the control of selectin counter-receptor structure and function. ImmunolRev. 2002;186:19–36.
43. Mitoma J, Bao X, Petryanik B, Schaerli P, Gauguet J-M, Yu S-Y, et al. Critical functions of N-glycans in L-selectin-mediated lymphocyte homing and recruitment. Nat Immunol. 2007;8:409–18.
44. Novokmet M, Lukić E, Vučković F, Ðurić Ž, Keser T, Rajšl K, et al. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Sci Rep. 2014;4:1–10.
45. Gudelj I, Baciarello M, Ugrina I, De Gregori M, Napolioni V, Ingelmo PM, et al. Changes in total plasma and serum N-glycome composition and patient-controlled analgesia after major abdominal surgery. Sci Rep. 2016;6:31234.
46. Dage JL, Ackermann BL, Halsall HB. Site localization of sialyl Lewis(x) antigen on alpha1-acid glycoprotein by high performance liquid chromatography-electrospray mass spectrometry. Glycobiology. 1998;8:755–60.
47. van Dijk W, Havenaar EC, Brinkman-van der Linden EC. Alpha 1-acid glycoprotein (orosomucoid): pathophysiological changes in glycosylation in relation to its function. Glycoconj J 1995;12:227–233.
48. Brinkman-van der Linden EC, van Ommen EC, van Dijk W. Glycosylation of alpha 1-acid glycoprotein in septic shock: changes in degree of branching and in expression of sialyl Lewis(x) groups. Glycoconj J. 1996;13:27–31.
49. Havenaar EC, Axford JS, Brinkman-van der Linden EC, Alavi A, Van Ommen EC, van het Hof B, et al. Severe rheumatoid arthritis prohibits the pregnancy-induced decrease in alpha3-fucosylation of alpha1-acid glycoprotein. Glycoconj J. 1998;15:723–9.
50. JM W, Fournet B, Konan D, Biou D, Durand G. 400-MHz 1H-NMR spectroscopy of fucosylated tetrasialyl oligosaccharides isolated from normal and cirrhotic alpha 1-acid glycoprotein. FEBS Lett. 1988;238:390–4.
51. EC B der L, de Haan PF, Havenaar EC, Van DW. Inflammation-induced expression of sialyl LewisX is not restricted to alpha1-acid glycoprotein but also occurs to a lesser extent on alpha1-antichymotrypsin and haptoglobin. GlycoconjJ. 1998;15:177–82.
52. Bondt A, Selman MHJ, Deelder AM, Hazes JMW, Willemsen SP, Wuhrer M, et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J Proteome Res. 2013;12:4522–31.
53. Pekelharing JM, Hepp E, Kamerling JP, Gerwig GJ, Leijnse B. Alterations in carbohydrate composition of serum IgG from patients with rheumatoid arthritis and from pregnant women. Ann Rheum Dis. 1988;47:91–5.
54. Trbojević Akmačić I, Ventham NT, Theodoratou E, Vučković F, Kennedy NA, Krištić J, et al. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflamm Bowel Dis. 2015;21:1237–47.
55. Sarphie TG. Interactions of IgG and [beta]-VLDL with aortic valve endothelium from hypercholesterolemic rabbits. Atherosclerosis. 1987;68:199–212.
56. •• Menni C, Gudelj I, MacDonald-Dunlop E, Mangino M, Zierer J, Bešić E, et al. Glycosylation profile of immunoglobulin G is cross-sectionally associated with cardiovascular disease risk score and subclinical atherosclerosis in two independent cohorts. Circ Res. 2018;CIRCRESAHA.117.312174. Very important: in this study, it is shown that alterations of IgG N -glycome are an independent risk factor for CVDs by itself and associated with traditional ones.
57. • Suzuki H, Chikada M, Yokoyama MK, Kurokawa MS, Ando T, Furukawa H, et al. Aberrant glycosylation of lumican in aortic valve stenosis revealed by proteomic analysis. Int Heart J. 2016;57:104–11. Important: this study showed that lumican is variously glycosylated and that highly glycosylated lumican molecules are decreased in aortic valve stenosis.
58. Wang X, Inoue S, Gu J, Miyoshi E, Noda K, Li W, et al. From the cover: dysregulation of TGF-1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc Natl Acad Sci 2005;102:15791–15796.
59. Wang X, Gu J, Ihara H, Miyoshi E, Honke K, Taniguchi N. Core fucosylation regulates epidermal growth factor receptor-mediated intracellular signaling. J Biol Chem. 2006;281:2572–7.
60. Makki N, Thiel KW, Miller FJ. The epidermal growth factor receptor and its ligands in cardiovascular disease. Int J Mol Sci. 2013;14:20597–613.
61. Rosenkranz S. TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004;63:423–32.
62. • Nagai-Okatani C, Minamino N. Aberrant glycosylation in the left ventricle and plasma of rats with cardiac hypertrophy and heart failure. PLoS One. 2016;11. Important: the authors in this study showed that glycosylation analysis can be a useful strategy for discovering of novel biomarkers for different diseases including cardiac hypertrophy and resultant heart failure.
63. Freeman LC, Lippold JJ, Mitchell KE. Glycosylation influences gating and pH sensitivity of I(sK) J Membr Biol 2000;177:65–79.
64. Ufret-Vincenty CA, Baro DJ, Santana LF, Schwetz TA, Norring SA, Ednie AR, et al. Differential contribution of sialic acid to the function of repolarizing K(+) currents in ventricular myocytes. Am J Physiol Cell Physiol. 2001;281:C464–74.
65. Fozzard HA, Kyle JW. Do defects in ion channel glycosylation set the stage for lethal cardiac arrhythmias? Sci STKE. 2002;2002:pe19.
66. Zhu J, Watanabe I, Gomez B, Thornhill WB. Determinants involved in Kv1 potassium channel folding in the endoplasmic reticulum, glycosylation in the golgi, and cell surface expression. J Biol Chem. 2001;276:39428–37.
67. Khanna R, Myers MP, Lainé M, Papazian DM. Glycosylation increases potassium channel stability and surface expression in mammalian cells. J Biol Chem. 2001;276:34028–34.
68. Shi G, Trimmer JS. Differential asparagine-linked glycosylation of voltage-gated K+ channels in mammalian brain and in transfected cells. J Membr Biol. 1999;168:265–73.
69. Akhavan A. N- and O-linked glycosylation coordinate cell-surface localization of a cardiac potassium channel. J Physiol. 2011;589:4647–8.
70. Ednie AR, Bennett ES. Reduced sialylation impacts ventricular repolarization by modulating specific K+ channel isoforms distinctly. J Biol Chem. 2015;290:2769–83.
71. Ufret-Vincenty CA, Baro DJ, Lederer WJ, Rockman HA, Quiñones LE, Santana LF. Role of sodium channel deglycosylation in the genesis of cardiac arrhythmias in heart failure. J Biol Chem. 2001;276:28197–203.
72. Recio-Pinto E, Thornhill WB, Duch DS, Levinson SR, Urban BW. Neuraminidase treatment modifies the function of electroplax sodium channels in planar lipid bilayers. Neuron. 1990;5:675–84.
73. Zhang Y, Hartmann HA, Satin J. Glycosylation influences voltage-dependent gating of cardiac and skeletal muscle sodium channels. J Membr Biol. 1999;171:195–207.
74. Bennett E, Urcan MS, Tinkle SS, Koszowski AG, Levinson SR. Contribution of sialic acid to the voltage dependence of sodium channel gating. A possible electrostatic mechanism. J Gen Physiol. 1997;109:327–43.
75. Tyrrell L, Renganathan M, Dib-Hajj SD, Waxman SG. Glycosylation alters steady-state inactivation of sodium channel Nav1.9/NaN in dorsal root ganglion neurons and is developmentally regulated. J Neurosci. 2001;21:9629–37.
76. Zuber C, Lackie PM, Catterall WA, Roth J. Polysialic acid is associated with sodium channels and the neural cell adhesion molecule N-CAM in adult rat brain. J Biol Chem. 1992;267:9965–71.
77. Bennett ES. Isoform-specific effects of sialic acid on voltage-dependent Na+ channel gating: functional sialic acids are localized to the S5-S6 loop of domain I. J Physiol. 2002;538:675–90.
78. Ednie AR, Harper JM, Bennett ES. Sialic acids attached to N- and O-glycans within the Nav1.4 D1S5-S6 linker contribute to channel gating. Biochim Biophys Acta - Gen Subj. 2015;1850:307–17.
79. • Deng W, Ednie AR, Qi J, Bennett ES. Aberrant sialylation causes dilated cardiomyopathy and stress-induced heart failure. Basic Res Cardiol. 2016;111. Important: in this study, the authors associated sialylation changes with cardiomyopathy and heart failure.
80. Montpetit ML, Stocker PJ, Schwetz T a, Harper JM, Norring S a, Schaffer L, et al. Regulated and aberrant glycosylation modulate cardiac electrical signaling. Proc Natl Acad Sci U S A 2009;106:16517–16522.
81. Vodovar N, Séronde MF, Laribi S, Gayat E, Lassus J, Boukef R, et al. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J. 2014;35:3434–41.
82. Peng J, Jiang J, Wang W, Qi X, Sun XL, Wu Q. Glycosylation and processing of pro-B-type natriuretic peptide in cardiomyocytes. Biochem Biophys Res Commun 2011;411:593–598.
83. Fenrick R, McNicoll N, De Léan A. Glycosylation is critical for natriuretic peptide receptor-B function. Mol Cell Biochem. 1996;165:103–9.
84. Nishikimi T, Ikeda M, Takeda Y, Ishimitsu T, Shibasaki I, Fukuda H, et al. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart. 2012;98:152–61.
85. Nishikimi T, Minamino N, Nakao K. Diverse molecular forms of plasma B-type natriuretic peptide in heart failure. Curr Heart Fail Rep. 2011;8:140–6.
86. Fenrick R, Bouchard N, McNicoll N, De Léan A. Glycosylation of asparagine 24 of the natriuretic peptide receptor-B is crucial for the formation of a competent ligand binding domain. Mol Cell Biochem 1997;173:25–32.
87. Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet. 2005;365:434–41.
88. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–9.
89. Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur J Clin Investig. 2007;37:925–32.
90. Ferrario M, Chiodini P, Chambless LE, Cesana G, Vanuzzo D, Panico S, et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol. 2005;34:413–21.
91. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2013:2014.
92. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743–53.
93. Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999;17:176–80.
94. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010;10:301–16.
95. Anthony RM, Nimmerjahn F. The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo. Curr Opin Organ Transplant. 2011;16:7–14.
96. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.
97. Yu X, Wang Y, Kristic J, Dong J, Chu X, Ge S, et al. Profiling IgG N-glycans as potential biomarker of chronological and biological ages. Medicine (Baltimore). 2016;95:e4112.
98. Krištić J, Vučković F, Menni C, Klarić L, Keser T, Beceheli I, et al. Glycans are a novel biomarker of chronological and biological ages. J Gerontol - Ser A Biol Sci Med Sci. 2014;69:779–89.
99. Parekh R, Roitt I, Isenberg D, Dwek R, Rademacher T. Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. J Exp Med. 1988;167:1731–6.
100. Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics 2011;10:M111.010090.
101. Yamada E, Tsukamoto Y, Sasaki R, Yagyu K, Takahashi N. Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconj J. 1997;14:401–5.
102. Vanhooren V, Desmyter L, Liu X-E, Cardelli M, Franceschi C, Federico A, et al. N-glycomic changes in serum proteins during human aging. Rejuvenation Res. 2007;10:521–531a.
103. Baković MP, Selman MHJ, Hoffmann M, Rudan I, Campbell H, Deelder AM, et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res. 2013;12:821–31.
104. • Plomp R, Ruhaak LR, Uh HW, Reiding KR, Selman M, Houwing-Duistermaat JJ, et al. Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. Sci Rep. 2017;7:12325. Important: this study shows that N -glycosylation changes of IgG are associated with inflammation and metabolic health.
105. Vanhooren V, Dewaele S, Libert C, Engelborghs S, De Deyn PP, Toussaint O, et al. Serum N-glycan profile shift during human ageing. Exp Gerontol. 2010;45:738–43.
106. Catera M, Borelli V, Malagolini N, Chiricolo M, Venturi G, Reis C, et al. Identification of novel plasma glycosylation-associated markers of aging. Oncotarget. 2016;7:7455–68.
107. Borelli V, Vanhooren V, Lonardi E, Reiding KR, Capri M, Libert C, et al. Plasma N-glycome signature of down syndrome. J Proteome Res. 2015;14:4232–45.
108. Capri M, Olivieri F, Lanzarini C, Remondini D, Borelli V, Lazzarini R, et al. Identification of miR-31-5p, miR-141-3p, miR-200c-3p, and GLT1 as human liver aging markers sensitive to donor–recipient age-mismatch in transplants. Aging Cell. 2017;16:262–72.
109. Ruhaak LR, Uh HW, Beekman M, Koeleman CAM, Hokke CH, Westendorp RGJ, et al. Decreased levels of bisecting GLcNAc glycoforms of IgG are associated with human longevity. PLoS One. 2010;5:1–8.
110. Harvey RE, Coffman KE, Miller VM. Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease. Ronée Womens Heal (l Engl). 2015;11:239–57.
111. Della Torre S, Maggi A. Sex differences: a resultant of an evolutionary pressure? Cell Metab 2017. p. 499–505, 25.
112. Arnold AP, Cassis LA, Eghbali M, Reue K, Sandberg K. Sex hormones and sex chromosomes cause sex differences in the development of cardiovascular diseases. Arterioscler Thromb Vasc Biol. 2017;37:746–56.
113. Regitz-Zagrosek V, Kararigas G. Mechanistic pathways of sex differences in cardiovascular disease. Physiol Rev. 2017;97:1–37.
114. Winham SJ, de Andrade M, Miller VM. Genetics of cardiovascular disease: importance of sex and ethnicity. Atherosclerosis. 2014;241:219–28.
115. Baetta R, Pontremoli M, Martinez Fernandez A, Spickett CM, Banfi C. Proteomics in cardiovascular diseases: unveiling sex and gender differences in the era of precision medicine. J Proteome. 2018;173:62–76.
116. Ding N, Sun HN, Sun W, Qu Y, Liu X, Yao Y, et al. Human serum N-glycan profiles are age and sex dependent. Age Ageing. 2011;40:568–75.
117. Chen G, Wang Y, Qiu L, Qin X, Liu H, Wang X, et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J Proteome. 2012;75:2824–34.
118. Van de Geijn FE, Wuhrer M, Selman MHJ, Willemsen SP, de Man YA, Deelder AM, et al. Immunoglobulin G galactosylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther. 2009;11
119. Ruhaak LR, Uh HW, Deelder AM, Dolhain REJM, Wuhrer M. Total plasma N-glycome changes during pregnancy. J Proteome Res. 2014;13:1657–68.
120. • Ercan A, Kohrt WM, Cui J, Deane KD, Pezer M, Yu EW, et al. Estrogens regulate glycosylation of IgG in women and men. JCI Insight. 2017;2:1–9. Important: this study shows that N -glycosylation is regulated by sex hormones.
121. De Jong SE, Selman MHJ, Adegnika AA, Amoah AS, Van Riet E, Kruize YCM, et al. IgG1 Fc N-glycan galactosylation as a biomarker for immune activation. Sci Rep. 2016;6
122. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155–67.
123. Lusis AJ. Atherosclerosis. Nature 2000. p. 233–241.
124. Huang J, Lee H, Zivkovic AM, Smilowitz JT, Rivera N, German JB, et al. Glycomic analysis of high density lipoprotein shows a highly sialylated particle. J Proteome Res. 2014;13:681–91.
125. Melajärvi N, Gylling H, Miettinen TA. Sialic acids and the metabolism of low density lipoprotein. J Lipid Res. 1996;37:1625–31.
126. Lindbohm N, Gylling H, R a R, T a M. Sialic acid content of low-density lipoprotein in women with coronary artery disease. J Lab Clin Med. 2000;136:110–5.
127. • Krishnan S, Shimoda M, Sacchi R, Kailemia MJ, Luxardi G, Kaysen GA, et al. HDL glycoprotein composition and site-specific glycosylation differentiates between clinical groups and affects IL-6 secretion in lipopolysaccharide-stimulated monocytes. Sci Rep. 2017;7. Important: this study shows that HDL glycosylation is an important feature for lipoprotein functions.
128. Savinova OV, Fillaus K, Jing L, Harris WS, Shearer GC. Reduced apolipoprotein glycosylation in patients with the metabolic syndrome. PLoS One. 2014;9:e104833.
129. • Krishnan S, Huang J, Lee H, Guerrero A, Berglund L, Anuurad E, et al. Combined high-density lipoprotein proteomic and glycomic profiles in patients at risk for coronary artery disease. J Proteome Res. 2015;14:5109–18. Important: in this study, the authors showed that HDL glycosylation can be used as a biomarker; HDL glycome distinguished between individuals who had coronary artery disease from those who did not within a group of individuals equally at risk for heart disease.
130. Marmillot P, Rao MN, Liu QH, Lakshman MR. Desialylation of human apolipoprotein E decreases its binding to human high-density lipoprotein and its ability to deliver esterified cholesterol to the liver. Metabolism. 1999;48:1184–92.
131. Boucher JG, Nguyen T, Sparks DL. Lipoprotein electrostatic properties regulate hepatic lipase association and activity. Biochem Cell Biol. 2007;85:696–708.
132. Harada LM, Carvalho MD t., Passarelli M, Quintão EC r. Lipoprotein desialylation simultaneously enhances the cell cholesterol uptake and impairs the reverse cholesterol transport system: in vitro evidences utilizing neuraminidase-treated lipoproteins and mouse peritoneal macrophages. Atherosclerosis 1998;139:65–75.
133. Orekhov AN, Tertov VV, Pokrovsky SN, Adamova IY, Martsenyuk ON, Lyakishev AA, et al. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res. 1988;62:421–9.
134. Tertov VV, Orekhov AN, Martsenyuk ON, Perova NV, Smirnov VN. Low-density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Exp Mol Pathol. 1989;50:337–47.
135. Chazov EI, Orekhov AN, Perova NV, Khashimov KA, Tertov VV, Lyakishev AA, et al. Atherogenicity of blood serum from patients with coronary heart disease. Lancet. 1986;328:595–8.
136. Orekhov AN, Bobryshev YV, Sobenin IA, Melnichenko AA, Chistiakov DA. Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease. Int J Mol Sci. 2014;15:12807–41.
137. Orekhov AN, Tertov VV, Mukhin DN, Mikhailenko IA. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem Biophys Res Commun. 1989;162:206–11.
138. Sobenin IA, Tertov V V., Koschinsky T, Bünting CE, Slavina ES, Dedovc II Slavina ES, Dedovc II, Orekhov AN Modified low density lipoprotein from diabetic patients causes cholesterol accumulation in human intimal aortic cells. Atherosclerosis 1993;100:41–54.
139. Tertov VV, Sobenin IA, Tonevitsky AG, Orekhov AN, Smirnov VN. Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography. Biochem Biophys Res Commun. 1990;167:1122–7.
140. Orekhov AN, Tertov VV, Sobenin IA, Smirnov VN, Via DP, Guevara JJ, et al. Sialic acid content of human low density lipoproteins affects their interaction with cell receptors and intracellular lipid accumulation. J Lipid Res. 1992;33:805–17.
141. Orekhov AN, Tertov VV, Mukhin DN. Desialylated low density lipoprotein—naturally occurring modified lipoprotein with atherogenic potency. Atherosclerosis. 1991;86:153–61.
142. Grewal T, Bartlett A, Burgess JW, Packer NH, Stanley KK. Desialylated LDL uptake in human and mouse macrophages can be mediated by a lectin receptor. Atherosclerosis. 1996;121:151–63.
143. Tertov VV, Sobenin IA, Gabbasov ZA, Popov EG, Orekhov AN. Lipoprotein aggregation as an essential condition of intracellular lipid accumulation caused by modified low density lipoproteins. Biochem Biophys Res Commun. 1989;163:489–94.
144. Bartlett AL, Grewal T, De Angelis E, Myers S, Stanley KK. Role of the macrophage galactose lectin in the uptake of desialylated LDL. Atherosclerosis. 2000;153:219–30.
145. Lindbohm N, Gylling H, Miettinen TE, T a M. Statin treatment increases the sialic acid content of LDL in hypercholesterolemic patients. Atherosclerosis. 2000;151:545–50.
146. Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014;13:159.
147. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132–40.
148. Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. J Nephrol. 2011;24:23–34.
149. • Wang Y, Klarić L, Yu X, Thaqi K, Dong J, Novokmet M, et al. The association between glycosylation of immunoglobulin G and hypertension. Med (United States). 2016;95. Important: in this study, the authors found that alterations of IgG N -glycome associate with hypertension.
150. Gao Q, Dolikun M, Štambuk J, Wang H, Zhao F, Yiliham N, et al. Immunoglobulin G N-glycans as potential postgenomic biomarkers for hypertension in the Kazakh population. Omi A J Integr Biol. 2017;21
151. Ito E, Oka R, Ishii T, Korekane H, Kurimoto A, Kizuka Y, et al. Fucosylated surfactant protein-D is a biomarker candidate for the development of chronic obstructive pulmonary disease. J Proteome. 2015;127:386–94.
152. Wahl A, Kasela S, Carnero-Montoro E, van Iterson M, Štambuk J, Sharma S, et al. IgG glycosylation and DNA methylation are interconnected with smoking. Biochim Biophys Acta - Gen Subj. 1862;2018:637–48.
153. Knezevic A, Gornik O, Polasek O, Pucic M, Redzic I, Novokmet M, et al. Effects of aging, body mass index, plasma lipid profiles, and smoking on human plasma N-glycans. Glycobiology. 2010;20:959–69.
154. Laclaustra M, Casasnovas JA, Fernández-Ortiz A, Fuster V, León-Latre M, Jiménez-Borreguero LJ, Pocovi M, Hurtado-Roca Y, Ordovas JM, Jarauta E, Guallar E, Ibañez B, Civeira F Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS study J Am Coll Cardiol 2016;67:1263–1274.
155. Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015;35:1544–50.
156. Testa R, Vanhooren V, Bonfigli AR, Boemi M, Olivieri F, Ceriello A, et al. N-Glycomic changes in serum proteins in type 2 diabetes mellitus correlate with complications and with metabolic syndrome parameters. PLoS One. 2015;10:e0119983.
157. Itoh N, Sakaue S, Nakagawa H, Kurogochi M, Ohira H, Deguchi K, et al. Analysis of N-glycan in serum glycoproteins from db/db mice and humans with type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;293:E1069–77.
158. Lemmers RFH, Vilaj M, Urda D, Agakov F, Šimurina M, Klaric L, et al. IgG glycan patterns are associated with type 2 diabetes in independent European populations. Biochim Biophys Acta - Gen Subj. 2017;1861(9):2240–9.
159. Rellier N, Ruggiero-Lopez D, Lecomte M, Lagarde M, Wiernsperger N. In vitro and in vivo alterations of enzymatic glycosylation in diabetes. Life Sci. 1999;64:1571–83.
160. Wolinsky H, Goldfischer S, Capron L, Capron F, Coltoff-Schiller B, Kasak L. Hydrolase activities in the rat aorta. I. Effects of diabetes mellitus and insulin treatment. Circ Res. 1978;42:821–31.
161. Lindberg G, Eklund GA, Gullberg B, Råstam L. Serum sialic acid concentration and cardiovascular mortality. BMJ. 1991;302:143–6.
162. Yokoyama H, Jensen JS, Jensen T, Deckert T. Serum sialic acid concentration is elevated in IDDM especially in early diabetic nephropathy. J Intern Med. 1995;237:519–23.
163. Akinkuolie AO, Buring JE, Ridker PM, Mora S. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014;3:e001221.
164. •• Lawler PR, Akinkuolie AO, Chandler PD, Moorthy M V., VanDenburgh MJ, Schaumberg DA, et al. Circulating N-linked glycoprotein acetyls and longitudinal mortality risk. Circ Res. 2016; Very important: this study showed that among initially healthy individuals, elevated baseline circulating glycoprotein N -acetyl methyl groups are associated with longitudinal risk of all-cause, cardiovascular, and cancer mortality.